Open Label Phase I Trial of intramyocardial AMG0001-01 administration in chronic heart failure patients with ischemic cardiomyopathy

Open Label Phase I Trial of intramyocardial AMG0001-01 administration in chronic heart failure patients with ischemic cardiomyopathy - Clinical Trial of intramyocardial AMG0001-01 administration in chronic heart failure patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012942

Enrollment

Registered

2014-07-01

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

10-spot administration of 0.4mg/0.2mL/site

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ischemic cardiomyopathy NYHA functional Class iii or iv LVEF<=40%

Exclusion criteria

Exclusion criteria: patient implanted with an LVAD thickness of left ventricular wall<5mm severe pulmonary hypertension

Design outcomes

Primary

Measure	Time frame
frequency of adverse event incidence for adverse event	—

Countries

Japan

Contacts

Public ContactShigeru miyagawa

osaka university hospital Cardiovascular surgery

miyagawa@surg1.med.osaka-u.ac.jp06-6879-3154

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026